Congresswoman Barbara Lee Condemns Ruling by Trump-Appointed Judge Undermining FDA Approval of Abortion Medication

Washington, DC – Congresswoman Barbara Lee (CA-12), Co-Chair of the Pro-Choice Caucus, released the following statement on Judge Matthew Kacsmaryk’s decision in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al to side with anti-abortion hate groups and suspend the FDA’s approval of mifepristone.

Mifepristone is the first drug in a two-medication regimen that has been used safely and effectively by millions of people for over 20 years for early abortion care and for miscarriage management.

“Study after study has found mifepristone to be an exceedingly safe and effective way to end a pregnancy; in fact, unfortunately, there are statistically more risks associated with pregnancy itself – especially for Black women. Since its approval by the FDA in 2000, mifepristone has been used safely by more than 5 million Americans. It is critical to remember right now that mifepristone is still legal and accessible, and we will not stop fighting to ensure it stays that way.

“Make no mistake: if the Supreme Court upholds this extreme and dangerous ruling, it will be the greatest loss for abortion rights since the fall of Roe. This is just the next step in the decades-long coordinated effort by anti-abortion groups to ban abortion care in every form, in every state.

“We can’t let that happen. As Co-Chair of the Pro-Choice Caucus, I am working closely with our partners to respond to this egregious ruling and preserve access to mifepristone nationwide. People—not politicians—should have the freedom to make their own health care decisions, and we won’t stop fighting until they do.”